Industry Research Reports

Home > Reports > Pharma & Healthcare > Direct Renin Inhibitors - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Direct Renin Inhibitors - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-01-24

Pages: 87 Pages

Report ld: 2341459

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Direct renin inhibition is a new means for blocking the renin–angiotensin system at the rate-limiting step of the cascade of events triggered by renin release—the interaction of renin with its physiological substrate angiotensinogen.

The global market for Direct Renin Inhibitors was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

North American market for Direct Renin Inhibitors was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Direct Renin Inhibitors was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for Direct Renin Inhibitors was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of Direct Renin Inhibitors include Noden Pharma, LGM Pharma and Cayman, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Direct Renin Inhibitors, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Direct Renin Inhibitors by region & country, by Type, and by Application.

The Direct Renin Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Direct Renin Inhibitors.

Market Segmentation

Report Metric
Details
Report Title
Direct Renin Inhibitors - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Direct Renin Inhibitors Companies Covered
Noden Pharma, LGM Pharma, Cayman
Global Direct Renin Inhibitors Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Direct Renin Inhibitors Market, Segment by Type
Aliskiren

Remikiren

Others
Global Direct Renin Inhibitors Market, Segment by Application
Hospital

Clinic

Others
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Direct Renin Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Direct Renin Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Direct Renin Inhibitors in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Direct Renin Inhibitors Product Introduction
    1.2 Global Direct Renin Inhibitors Market Size Forecast
        1.2.1 Global Direct Renin Inhibitors Sales Value (2019-2030)
        1.2.2 Global Direct Renin Inhibitors Sales Volume (2019-2030)
        1.2.3 Global Direct Renin Inhibitors Sales Price (2019-2030)
    1.3 Direct Renin Inhibitors Market Trends & Drivers
        1.3.1 Direct Renin Inhibitors Industry Trends
        1.3.2 Direct Renin Inhibitors Market Drivers & Opportunity
        1.3.3 Direct Renin Inhibitors Market Challenges
        1.3.4 Direct Renin Inhibitors Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Direct Renin Inhibitors Players Revenue Ranking (2023)
    2.2 Global Direct Renin Inhibitors Revenue by Company (2019-2024)
    2.3 Global Direct Renin Inhibitors Players Sales Volume Ranking (2023)
    2.4 Global Direct Renin Inhibitors Sales Volume by Company Players (2019-2024)
    2.5 Global Direct Renin Inhibitors Average Price by Company (2019-2024)
    2.6 Key Manufacturers Direct Renin Inhibitors Manufacturing Base Distribution and Headquarters
    2.7 Key Manufacturers Direct Renin Inhibitors Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of Direct Renin Inhibitors
    2.9 Direct Renin Inhibitors Market Competitive Analysis
        2.9.1 Direct Renin Inhibitors Market Concentration Rate (2019-2024)
        2.9.2 Global 5 and 10 Largest Manufacturers by Direct Renin Inhibitors Revenue in 2023
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct Renin Inhibitors as of 2023)
    2.10 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Aliskiren
        3.1.2 Remikiren
        3.1.3 Others
    3.2 Global Direct Renin Inhibitors Sales Value by Type
        3.2.1 Global Direct Renin Inhibitors Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Direct Renin Inhibitors Sales Value, by Type (2019-2030)
        3.2.3 Global Direct Renin Inhibitors Sales Value, by Type (%) (2019-2030)
    3.3 Global Direct Renin Inhibitors Sales Volume by Type
        3.3.1 Global Direct Renin Inhibitors Sales Volume by Type (2019 VS 2023 VS 2030)
        3.3.2 Global Direct Renin Inhibitors Sales Volume, by Type (2019-2030)
        3.3.3 Global Direct Renin Inhibitors Sales Volume, by Type (%) (2019-2030)
    3.4 Global Direct Renin Inhibitors Average Price by Type (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Hospital
        4.1.2 Clinic
        4.1.3 Others
    4.2 Global Direct Renin Inhibitors Sales Value by Application
        4.2.1 Global Direct Renin Inhibitors Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Direct Renin Inhibitors Sales Value, by Application (2019-2030)
        4.2.3 Global Direct Renin Inhibitors Sales Value, by Application (%) (2019-2030)
    4.3 Global Direct Renin Inhibitors Sales Volume by Application
        4.3.1 Global Direct Renin Inhibitors Sales Volume by Application (2019 VS 2023 VS 2030)
        4.3.2 Global Direct Renin Inhibitors Sales Volume, by Application (2019-2030)
        4.3.3 Global Direct Renin Inhibitors Sales Volume, by Application (%) (2019-2030)
    4.4 Global Direct Renin Inhibitors Average Price by Application (2019-2030)

 5 Segmentation by Region
    5.1 Global Direct Renin Inhibitors Sales Value by Region
        5.1.1 Global Direct Renin Inhibitors Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Direct Renin Inhibitors Sales Value by Region (2019-2024)
        5.1.3 Global Direct Renin Inhibitors Sales Value by Region (2025-2030)
        5.1.4 Global Direct Renin Inhibitors Sales Value by Region (%), (2019-2030)
    5.2 Global Direct Renin Inhibitors Sales Volume by Region
        5.2.1 Global Direct Renin Inhibitors Sales Volume by Region: 2019 VS 2023 VS 2030
        5.2.2 Global Direct Renin Inhibitors Sales Volume by Region (2019-2024)
        5.2.3 Global Direct Renin Inhibitors Sales Volume by Region (2025-2030)
        5.2.4 Global Direct Renin Inhibitors Sales Volume by Region (%), (2019-2030)
    5.3 Global Direct Renin Inhibitors Average Price by Region (2019-2030)
    5.4 North America
        5.4.1 North America Direct Renin Inhibitors Sales Value, 2019-2030
        5.4.2 North America Direct Renin Inhibitors Sales Value by Country (%), 2023 VS 2030
    5.5 Europe
        5.5.1 Europe Direct Renin Inhibitors Sales Value, 2019-2030
        5.5.2 Europe Direct Renin Inhibitors Sales Value by Country (%), 2023 VS 2030
    5.6 Asia Pacific
        5.6.1 Asia Pacific Direct Renin Inhibitors Sales Value, 2019-2030
        5.6.2 Asia Pacific Direct Renin Inhibitors Sales Value by Country (%), 2023 VS 2030
    5.7 South America
        5.7.1 South America Direct Renin Inhibitors Sales Value, 2019-2030
        5.7.2 South America Direct Renin Inhibitors Sales Value by Country (%), 2023 VS 2030
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa Direct Renin Inhibitors Sales Value, 2019-2030
        5.8.2 Middle East & Africa Direct Renin Inhibitors Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Direct Renin Inhibitors Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Direct Renin Inhibitors Sales Value
        6.2.1 Key Countries/Regions Direct Renin Inhibitors Sales Value, 2019-2030
        6.2.2 Key Countries/Regions Direct Renin Inhibitors Sales Volume, 2019-2030
    6.3 United States
        6.3.1 United States Direct Renin Inhibitors Sales Value, 2019-2030
        6.3.2 United States Direct Renin Inhibitors Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Direct Renin Inhibitors Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Direct Renin Inhibitors Sales Value, 2019-2030
        6.4.2 Europe Direct Renin Inhibitors Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Direct Renin Inhibitors Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Direct Renin Inhibitors Sales Value, 2019-2030
        6.5.2 China Direct Renin Inhibitors Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Direct Renin Inhibitors Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Direct Renin Inhibitors Sales Value, 2019-2030
        6.6.2 Japan Direct Renin Inhibitors Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Direct Renin Inhibitors Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Direct Renin Inhibitors Sales Value, 2019-2030
        6.7.2 South Korea Direct Renin Inhibitors Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Direct Renin Inhibitors Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Direct Renin Inhibitors Sales Value, 2019-2030
        6.8.2 Southeast Asia Direct Renin Inhibitors Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Direct Renin Inhibitors Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Direct Renin Inhibitors Sales Value, 2019-2030
        6.9.2 India Direct Renin Inhibitors Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Direct Renin Inhibitors Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Noden Pharma
        7.1.1 Noden Pharma Company Information
        7.1.2 Noden Pharma Introduction and Business Overview
        7.1.3 Noden Pharma Direct Renin Inhibitors Sales, Revenue and Gross Margin (2019-2024)
        7.1.4 Noden Pharma Direct Renin Inhibitors Product Offerings
        7.1.5 Noden Pharma Recent Development
    7.2 LGM Pharma
        7.2.1 LGM Pharma Company Information
        7.2.2 LGM Pharma Introduction and Business Overview
        7.2.3 LGM Pharma Direct Renin Inhibitors Sales, Revenue and Gross Margin (2019-2024)
        7.2.4 LGM Pharma Direct Renin Inhibitors Product Offerings
        7.2.5 LGM Pharma Recent Development
    7.3 Cayman
        7.3.1 Cayman Company Information
        7.3.2 Cayman Introduction and Business Overview
        7.3.3 Cayman Direct Renin Inhibitors Sales, Revenue and Gross Margin (2019-2024)
        7.3.4 Cayman Direct Renin Inhibitors Product Offerings
        7.3.5 Cayman Recent Development

 8 Industry Chain Analysis
    8.1 Direct Renin Inhibitors Industrial Chain
    8.2 Direct Renin Inhibitors Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Direct Renin Inhibitors Sales Model
        8.5.2 Sales Channel
        8.5.3 Direct Renin Inhibitors Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures